Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 2/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.46 |
| ▸ | TSHR | P16473 | 2/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | PRCP | P42785 | 1/20 | 0.40 |
| ▸ | SLC6A3 | Q01959 | 4/20 | 0.40 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.40 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.40 |
| ▸ | DHFR | P00374 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.38 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.38 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.38 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.38 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL40033 | 1.00 | CYP3A4 (0.46) | CYP3A4CYP2D6TSHRCYP2C9CYP1A2 | |
| SCHEMBL40034 | 1.00 | CYP3A4 (0.46) | CYP3A4CYP2D6TSHRCYP2C9CYP1A2 | |
| SCHEMBL15384851 | 0.98 | CYP3A4 (0.45) | CYP3A4CYP2D6TSHRCYP2C9CYP1A2 | |
| Hydrochloric Acid SCHEMBL132158 | 0.98 | TSHR (0.45) | CYP3A4CYP2D6TSHRCYP2C9CYP1A2 | |
| SCHEMBL17919051 | 0.98 | CYP3A4 (0.45) | CYP3A4CYP2D6TSHRCYP2C9CYP1A2 | |
| SCHEMBL1688457 | 0.98 | CYP3A4 (0.45) | CYP3A4CYP2D6TSHRCYP2C9CYP1A2 | |
| Hydrochloric Acid SCHEMBL134642 | 0.98 | TSHR (0.45) | CYP3A4CYP2D6TSHRCYP2C9CYP1A2 | |
| Hydrochloric Acid SCHEMBL1899822 | 0.98 | TSHR (0.45) | CYP3A4CYP2D6TSHRCYP2C9CYP1A2 | |
| SCHEMBL16946146 | 0.98 | CYP3A4 (0.45) | CYP3A4CYP2D6TSHRCYP2C9CYP1A2 | |
| Hydrochloric Acid SCHEMBL15206077 | 0.96 | TSHR (0.44) | CYP3A4CYP2D6TSHRCYP2C9CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 130 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116735748-A | Chiral purity detection method for (R) -piperidine-2-methyl formate hydrochloride | 上海吉奉生物科技有限公司 | 2023-09-12 | — | — | CN | claimed |
| US-12624003-B2 | Carboxylic acid containing indanyl compounds for the treatment of neurodegenerative diseases | CELGENE CORPORATION (US) | 2026-05-12 | — | — | US | disclosed |
| US-20260098060-A1 | MACROCYCLIC CFTR MODULATORS | IDORSIA PHARMACEUTICALS LTD (CH) | 2026-04-09 | — | — | US | disclosed |
| EP-4267117-B1 | CARBOXYLIC ACID CONTAINING INDANYL COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | CELGENE CORP (US) | 2026-04-08 | — | — | EP | disclosed |
| US-20260000781-A1 | FC CONJUGATES INCLUDING AN INHIBITOR OF CD73 AND USES THEREOF | CIDARA THERAPEUTICS INC (US) | 2026-01-01 | — | — | US | disclosed |
| EP-4587443-A1 | MACROCYCLIC CFTR MODULATORS | Idorsia Pharmaceuticals Ltd (CH) | 2025-07-23 | — | — | EP | disclosed |
| EP-4551563-A2 | FC CONJUGATES INCLUDING AN INHIBITOR OF CD73 AND USES THEREOF | CIDARA THERAPEUTICS, INC. (US) | 2025-05-14 | — | — | EP | disclosed |
| CN-119816487-A | FC conjugates comprising CD73 inhibitors and uses thereof | 奇达拉治疗公司 | 2025-04-11 | — | — | CN | disclosed |
| WO-2025064869-A2 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF CANCER | CIDARA THERAPEUTICS, INC. (US) | 2025-03-27 | — | — | WO | disclosed |
| WO-2024213044-A1 | AZACYCLO-CARBONYL-FUSED RING DERIVATIVES AND USE THEREOF | Beijing Double-Crane Runchuang Technology Co., Ltd. (CN) | 2024-10-17 | — | — | WO | disclosed |
| US-20100184739-A1 | Modulators of ATP-Binding Cassette Transporters | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-07-22 | — | — | US | disclosed |
| WO-2008150118-A2 | NOVEL AMIDE DERIVATIVE FOR INHIBITING THE GROWTH OF CANCER CELLS | HANMI PHARM. CO., LTD. (KR) | 2008-12-11 | — | — | WO | disclosed |
| US-20070099934-A1 | N-aryl piperidine substituted biphenylcarboxamides as inhibitors of apolipoprotein b | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-05-03 | — | — | US | disclosed |
| EP-1694644-A2 | N-ARYL PIPERIDINE SUBSTITUTED BIPHENYLCARBOXAMIDES AS INHIBITORS OF APOLIPOPROTEIN B | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-08-30 | — | — | EP | disclosed |
| WO-2005058824-A2 | N-ARYL PIPERIDINE SUBSTITUTED BIPHENYLCARBOXAMIDES AS INHIBITORS OF APOLIPOPROTE IN B | JANSSEN PHARMACEUTICA N.V. (BE) | 2005-06-30 | — | — | WO | disclosed |
| CN-1093125-C | Sulfamide-metalloprotease inhibitors | HOFFMANN LA ROCHE (CH) | 2002-10-23 | — | — | CN | disclosed |
| CN-1250445-A | Sulfamide-metalloprotease inhibitors | HOFFMANN LA ROCHE (CH) | 2000-04-12 | — | — | CN | disclosed |
| CN-1027695-C | Heterocyclic-NMDA antagonists | MERRELL DOW PHARMA (US) | 1995-02-22 | — | — | CN | disclosed |
| CN-1056499-A | HETEROCYCLIC-NMDA ANTAGONISTS | MERRELL DOW PHARMA (US) | 1991-11-27 | — | — | CN | disclosed |
| US-4760065-A | Trans(-)-10aR-7,8,9,10,10a,11-hexahydro-2-trifluoromethyl -13H-pyrido(1',2':3, 4)imidazo(2, 1b)quinozoline-13-one | HARDTMANN GOETZ E (US) | 1988-07-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100184739-A1 | Modulators of ATP-Binding Cassette Transporters | CFTR, ABCB1, ABCC2 | CYP3A4 1862/4885CYP2D6 1732/4885TSHR 2753/4885 |
| US-20260098060-A1 | MACROCYCLIC CFTR MODULATORS | CFTR, CLIC1, ARRB1 | CYP3A4 857/4885CYP2D6 440/4885TSHR 701/4885 |
| US-20070099934-A1 | N-aryl piperidine substituted biphenylcarboxamides as inhibitors of apolipoprotein b | APOB, PNLIP, LIPC | CYP3A4 1066/4885CYP2D6 1104/4885TSHR 2816/4885 |
| US-12624003-B2 | Carboxylic acid containing indanyl compounds for the treatment of neurodegenerative diseases | S1PR5, LPAR5, S1PR2 | CYP3A4 3400/4885CYP2D6 1724/4885TSHR 1869/4885 |
| US-20260000781-A1 | FC CONJUGATES INCLUDING AN INHIBITOR OF CD73 AND USES THEREOF | FCGR2A, FCGR1A, FCGR3B | CYP3A4 2895/4885CYP2D6 1832/4885TSHR 842/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.